UCB (PK) Quote - UCBJY

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

100.40

Bid

98.32

Offer

101.50

Volume

4,128

99.49 Day's Range 100.43

43.174 52 Week Range 100.43

Market Cap

38.071B

Previous Close

99.24

Open

99.61

Last Trade

100.4

Last Trade Time

Financial Volume

US$ 413,733

VWAP

100.2261

Average Volume (3m)

21,316

Shares Outstanding

379,189,796

Dividend Yield

0.92%

PE Ratio

212.97

Earnings Per Share (EPS)

0.9

Revenue

4.87B

Net Profit

343M

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

Pharmaceutical Preparations

Industry

Chemicals & Allied Products

Website

www.ucb.com

Headquarters

Brussels, Brussels-capital Region, Bel

Founded

1928

UCB (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker UCBJY. The last closing price for UCB (PK) was US$99.24. Over the last year, UCB (PK) shares have traded in a share price range of US$ 43.174 to US$ 100.43.

UCB (PK) currently has 379,189,796 shares in issue. The market capitalisation of UCB (PK) is US$37.63 billion. UCB (PK) has a price to earnings ratio (PE ratio) of 212.97.

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services Judges highlight value-added partnership and finance transformation as leading examples of innovation in...

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S. Results of retrospective analysis show use of newer anti-epilepsy drugs, access to...

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015 PR Newswire ATLANTA, May 16, 2015 ATLANTA, May 16, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company...

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam - Major milestone for brivaracetam is latest step towards UCB goal of extending treatment...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annual Meeting PR Newswire ATLANTA, Dec. 8, 2014 ATLANTA, Dec. 8, 2014...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy -- Primary efficacy and safety...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	4.65	4.85639686684	95.75	100.43	95.2425	7158	98.85944824	DR
4	3.23	3.3240712154	97.17	100.43	94.206	6800	97.13780688	DR
12	8.88	9.7027972028	91.52	100.43	86.71	21316	94.86626183	DR
26	26.56	35.9696641387	73.84	100.43	73.515	16437	89.9382685	DR
52	56.84	130.486685032	43.56	100.43	43.174	17601	75.2216204	DR
156	43.67	76.9786708972	56.73	100.43	32.82	20915	51.21709302	DR
260	61.2125	156.20414673	39.1875	100.43	32.45	20087	52.49834149	DR

UCBJY - Frequently Asked Questions (FAQ)

What is the current UCB (PK) share price?

The current share price of UCB (PK) is US$ 100.40

How many UCB (PK) shares are in issue?

UCB (PK) has 379,189,796 shares in issue

What is the market cap of UCB (PK)?

The market capitalisation of UCB (PK) is USD 37.63B

What is the 1 year trading range for UCB (PK) share price?

UCB (PK) has traded in the range of US$ 43.174 to US$ 100.43 during the past year

What is the PE ratio of UCB (PK)?

The price to earnings ratio of UCB (PK) is 212.97

What is the cash to sales ratio of UCB (PK)?

The cash to sales ratio of UCB (PK) is 15.01

What is the reporting currency for UCB (PK)?

UCB (PK) reports financial results in EUR

What is the latest annual turnover for UCB (PK)?

The latest annual turnover of UCB (PK) is EUR 4.87B

What is the latest annual profit for UCB (PK)?

The latest annual profit of UCB (PK) is EUR 343M

What is the registered address of UCB (PK)?

The registered address for UCB (PK) is 60, ALLEE DE LA RECHERCHE, BRUSSELS, BRUSSELS-CAPITAL REGION, B-1070

What is the UCB (PK) website address?

The website address for UCB (PK) is www.ucb.com

Which industry sector does UCB (PK) operate in?

UCB (PK) operates in the CHEMICALS & ALLIED PRODUCTS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DTEMFDitem Explorations (CE)	US$ 0.01 (999,900.00%)	1,000
RRMLFRoss River Minerals Inc (CE)	US$ 0.0089 (889,900.00%)	9.95k
FGHFFForte Group Holdings Inc (PK)	US$ 0.3833 (29,384.62%)	432
PRMDPrimeMD Inc (CE)	US$ 0.0002 (19,900.00%)	100
SDCCQSmileDirectClub Inc (CE)	US$ 0.0002 (19,900.00%)	392.07k
CDJMCarnegie Development Inc (CE)	US$ 0.000001 (-100.00%)	2.58k
RAHGFRoan Holdings Group Company Ltd (CE)	US$ 0.000001 (-99.99%)	200
UBMRFUrbanimmersive Inc (CE)	US$ 0.000001 (-99.97%)	1.5k
UNDRUnderSea Recovery Corporation (CE)	US$ 0.000001 (-99.90%)	55k
EICCFE Automotive Inc (CE)	US$ 0.0001 (-99.88%)	5.67k
PHILPHI Group Inc (PK)	US$ 0.0005 (0.00%)	562.38M
GRLFGreen Leaf Innovations Inc (PK)	US$ 0.0001 (0.00%)	284.6M
RDARRaadr Inc (PK)	US$ 0.0016 (-5.88%)	170.08M
HMBLHUMBL Inc (PK)	US$ 0.00085 (6.25%)	153.18M
CGACCode Green Apparel Corp (PK)	US$ 0.0004 (-11.11%)	113.22M